Request Trial
shutterstock_1414222322_chris_redan
Chris Redan / Shutterstock.com
6 April 2021BiotechClare Roskell and Samantha Moodie

EPO’s new examination guidelines: what you need to know

A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026   Judges dismissed an appeal from MSN Laboratories, which was hoping to show that several patents covering Cabometyx were invalid and would not be infringed by its generic product.
Biotech
Tempus AI bid to derail DNA patent case hits snag
31 August 2026   Efforts to shut down an eight-patent dispute over cancer-detection technology have run into a hurdle in a Delaware federal court.
Biotech
China-origin biotech assets and the hidden question of IP ownership
27 August 2026   As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler


Editor's picks

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026

Editor's picks

Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

More features

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Tempus AI bid to derail DNA patent case hits snag
FDA targets faster generic approvals in drive to slash drug prices
China-origin biotech assets and the hidden question of IP ownership
The buyers' wishlist: What makes a life sciences deal stack up?
Stris & Maher opens new Dallas office with partner hires
10x Genomics dealt major blow in sequencing fight
Abbott fends off Chinese rival’s patent challenge at UPC